Alnylam Pharmaceuticals, Inc. (ALNY)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $32.85B
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Latest financial period: June 30, 2026
Filed with the SEC: July 30, 2026
Estimated earnings date: October 29, 2026
Not currently ranked. Fewer than eight consecutive quarters are available.
Profit Not currently ranked
Growth Not currently ranked
Payout Not currently ranked
Safety Not currently ranked
Price Not currently ranked
